On the 19th, PHC Holdings <6523.T> announced that its subsidiary PHC has developed a new production technology in collaboration with Cyfuse <4892.T> based on a business partnership and joint research aimed at commercialization in the field of regenerative and cell medicine.
According to the company, this technology enables real-time monitoring of cell quality for "living cells" and "three-dimensional cells," which have been technically challenging until now, leading to improvements in the quality of cell products and stable manufacturing. Specifically, by combining the three-dimensional cell structures manufactured using Cyfuse's proprietary foundational technology "Bio 3D Printing" with the In-Line monitoring technology installed in the automatic culture device "LiCellGrow" currently under development by PHC, improvements and stabilization of cell product quality have been achieved.
As of 2:21 PM, the stock price is 1,075 yen, up 4 yen from the previous day.
Provided by Wealth Advisor Company.
Comment(0)
Reason For Report